Editorial
GLP-1 weight-loss jabs: hype vs reality
Oliver Mackman · Editorial director · Best Business Loans Ltd (16833937)
Last updated 2026-06-10
GLP-1 weight-loss medication is genuinely effective, but it is a long-term medical treatment, not a quick cure. In trials, semaglutide produced average weight loss around 15 percent of body weight and tirzepatide around 20 percent, far beyond what most diets achieve. The reality the marketing tends to skip is that the weight returns for most people who stop, side effects are common, it suits some people and not others, and a prescriber decides whether it is appropriate. This page is editorial commentary, not clinical advice.
What is real
- · The efficacy is real. Average trial weight loss of roughly 15 percent (semaglutide) and 20 percent (tirzepatide) is a step change over diet and exercise alone.
- · The benefits can extend beyond weight. Licensed indications now include cardiovascular risk reduction and obstructive sleep apnoea for eligible patients.
- · For many people with obesity or weight-related conditions, it is a serious, evidence-backed option their clinician may recommend.
What gets oversold
- · The "miracle" framing. It is a tool that works alongside food, protein, sleep and movement, not a replacement for them.
- · The idea that it is a one-off fix. Most people regain a large share of the weight after stopping. Roughly 82 percent regain at least a quarter of lost weight within a year of stopping (Oxford analysis, 2026). See our aftercare hub.
- · The silence on side effects. Nausea, reflux, constipation and fatigue are common, especially during dose increases, and hair shedding has been reported.
- · The "for everyone" tone. It is a prescription-only medicine with eligibility criteria, contraindications and a cost that many cannot sustain long term.
The bits people do not talk about enough
Cost and continuity matter. Private treatment is an ongoing monthly expense, and stopping because of cost is one of the most common reasons people regain weight. Muscle loss is real too: up to around half of the weight lost can be non-fat unless protein and resistance training are kept up, which is why aftercare planning is part of the treatment, not an afterthought.
There is also a stigma problem in both directions. Some people feel judged for using medication; others are sold it as an effortless shortcut. Neither framing is accurate. It is a medical treatment for a medical condition, with real benefits and real trade-offs, best decided with a UK-licensed prescriber who knows your history.
Frequently asked questions
Do GLP-1 jabs actually work?
Yes, the trial evidence is strong: average weight loss of around 15 percent for semaglutide and around 20 percent for tirzepatide, well beyond diet and exercise alone. The caveat is that the effect depends on staying on treatment and supporting it with nutrition and activity.
Will I keep the weight off after stopping?
Most people regain a significant share of the weight after stopping. Roughly 82 percent regain at least a quarter within a year. Maintenance dosing, resistance training and high protein reduce, but do not eliminate, that regain.
Is it a healthy way to lose weight?
For eligible patients under clinical supervision it is an evidence-based option, but it is not risk-free and it is not right for everyone. Side effects are common and muscle loss is a real risk without protein and training. Whether it is appropriate for you is a decision for your prescriber.
Is GLP-1 medication a cure for obesity?
No. It is an effective long-term treatment that manages weight while it is being taken, similar to how blood-pressure medication manages blood pressure. It is not a one-off cure, which is why aftercare and maintenance planning matter.
Related: aftercare and regain · ASA advertising rules · NHS access.